All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On 18th May 2017, in a letter to the Editor of Blood, Caroline Gay from the Service de Pharmacie, Centre Hospitalier Universitaire (CHU) de Rennes, Rennes, France, and colleagues reported on their study which aimed to assess the effect of doxorubicin dose capping in DLBCL patients.
Recently, there has been uncertainty of the toxicity that arises with high doses of anthracycline therapy in patients with elevated Body Surface Area (BSA). To determine this, an analysis of 1,384 patients with DLBCL receiving first-line treatment who enrolled in four different clinical trials (LNH98-5, LNH-75, LNH03-2B, and LNH03-6B) was carried out.
All patients had been administered R-CHOP or an R-CHOP-like (mainly R-ACVBP) regimen. Using Mosteller’s formula, a theoretical BSA was estimated for each patient based on their height and weight at study inclusion. By comparing the theoretical dose (planned protocol dose) and observed dose (what the patient actually received), it could be determined if dose capping had taken place. The cutoff value for BSA was 2.1m2.
The letter concluded by stating that capping doxorubicin dose at 2m2 did not result in inferior efficacy in patients with DLBCL and elevated BSA. In addition, uncapped doses did not result in an increased incidence of treatment related mortality. Thus, uncapped or capped doxorubicin appears acceptable in patients with DLBCL and elevated BSA.
However, the authors cautioned readers when interpreting their results due to a few limitations of the study, such as its unplanned retrospective nature and its small sample size.
N/A
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox